Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Michigan: - MyMichigan Medical Center Gratiot — Alma, Michigan
- MyMichigan Medical Center Alpena — Alpena, Michigan
- Trinity Health IHA - Obstetrics and Gynecology West Arbor — Ann Arbor, Michigan
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
Phase 3 Recruiting Academic/Other
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
- Trinity Health Medical Center - Canton — Canton, Michigan
Phase 3 Recruiting Network
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Michigan: - Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
- Henry Ford Macomb Hospital-Clinton Township — Clinton Township, Michigan
- Henry Ford Medical Center-Fairlane — Dearborn, Michigan
- Henry Ford Hospital — Detroit, Michigan
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Michigan: - University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital — Grand Rapids, Michigan
Phase 3 Recruiting Industry
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…
Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Michigan: - Local Institution - 2105 — Ann Arbor, Michigan
- Local Institution - 2111 — Detroit, Michigan
- Local Institution - 2140 — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
Phase 2 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…
Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Michigan: - University Of Michigan /ID# 273511 — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, two-part trial in participants with FAP.
Sponsor: Recursion Pharmaceuticals Inc.
NCT ID: NCT05552755
Sites in Michigan: - Corewell Health (Spectrum Health Hospitals Colorectal Cancer Multis) — Grand Rapids, Michigan
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Michigan: - Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts) a…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05379595
Sites in Michigan: - University of Michigan Health System — Ann Arbor, Michigan
- Start Midwest — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…
Sponsor: Arvinas Inc.
NCT ID: NCT07023731
Sites in Michigan: - Clinical Trial Site — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Michigan: - Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Michigan: - START Midwest — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Sponsor: Verastem, Inc.
NCT ID: NCT07020221
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uv…
Sponsor: IDEAYA Biosciences
NCT ID: NCT03947385
Sites in Michigan: - Cancer Hematology Centers Western Michigan — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
Sponsor: Apollo Therapeutics Ltd
NCT ID: NCT06399757
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibi…
Sponsor: Medicenna Therapeutics, Inc.
NCT ID: NCT05086692
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its i…
Sponsor: Lantheus Medical Imaging
NCT ID: NCT06298916
Sites in Michigan: - BAMF Health, Inc. — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoper…
Sponsor: Radiopharm Theranostics, Ltd
NCT ID: NCT07189871
Sites in Michigan: - BAMF Health — Grand Rapids, Michigan
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the tumor.
Sponsor: Washington University School of Medicine
NCT ID: NCT03516708
Sites in Michigan: - Henry Ford Cancer Institute — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06730750
Sites in Michigan: - START Midwest — Grand Rapids, Michigan